Abstract
Serum samples from 320 women with chromosomally normal fetuses and from 50 women with fetuses affected by Down's syndrome were assayed retrospectively for human chorionic gonadotropin (hCG), pregnancy-specificβ 1 glycoprotein (SP1), alpha fetoprotein (AFP), and unconjugated estriol (uE3) between 14 and 21 weeks of gestation. Nonparametric discriminant analysis was applied to calculate Down syndrome risks on the basis of various combinations of serum parameters. At a risk threshold that falsely identifies 5% of controls as being affected, 46 to 48% of Down syndrome pregnancies were detected by combinations of hCG/AFP, hCG/AFP/uE3, and hCG/AFP/uE3/SP1 respectively. HCG, AFP, and uE3 were assayed in 652 serum samples from women who underwent amniocentesis because of maternal age (≥35 years in this prospective study). 49% of women with euploid fetal karyotype, 8 of 10 pregnancies with Down's syndrome, and 3 pregnancies with sex chromosomal anomalies were identified as being at an increased risk (>1:380).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bartels I, Lindemann A (1988) Maternal levels of pregnancy-specificβ 1-glycoprotein (SP-1) are elevated in pregnancies affected by Down's syndrome. Hum Genet 80:46–48
Bartels I, Thiele M, Bogart MH (1990) Maternal serum hCG and SP1 in pregnancies with fetal aneuploidy. Am J Med Genet 37:261–264.
Bogart MH, Pandian MR, Jones OW (1987) Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 7:623–630
Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ (1988) Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 95:330–333
Crossley JA, Aitken DA, Connor JM (1991) Prenatal screening for chromosome abnormalities using maternal serum chorionic gonadotrophin, alpha-fetoprotein, and age. Prenat Diagn 11:83–101
Graham GW, Crossley JA, Aitken DA, Connor JM (1992) Variation in the levels of pregnancy-specificβ-1-glycoprotein in maternal serum from chromosomally abnormal pregnancies. Prenat Diagn 12:505–512
Hershey DW, Crandall BF, Perdue S (1986) Combining maternal age and serumα-fetoprotein to predict the risk of Down syndrome. Obstet Gynecol 68:177–180
Hook EB (1981) Rates of chromosome abnormalities at different maternal ages. Obstet Gynecol 58:282–285
MacDonald ML, Wagner RM, Slotnick RN (1991) Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age. Obstet Gynecol 77:63–68
Mancini G, Perona M, Dall'Amico D, Bollati C, Albano F, Mazzone R, Rosso M, Carbonara AO (1991) Screening for fetal Down's syndrome with maternal serum markers — An experience in Italy. Prenat Diagn 11:245–252
Merkatz IR, Nitwosky HM, Macri JN, Johnson WE (1984) An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 148:886–894
Norgaard-Pedersen B, Larsen SO, Abends J, Svenstrup B, Tabor A (1990) Maternal serum markers in screening for Down syndrome. Clin Genet 37:35–43
Petrocik E, Wassman ER, Lee JJ, Kelly JC (1990) Second trimester maternal serum pregnancy specific Beta-1 glycoprotein (SP-1) levels in normal and Down syndrome pregnancies. Am J Med Genet 37:114–118
Statistisches Bundesamt (ed): Statistisches Jahrbuch 1990 für die Bundesrepublik Deutschland. Stuttgart, Metzler-Poeschel, p 1190
Voss P, Linneke P, Haller G, Severin W, Jeske W (1986) Keine Altersabhängigkeit bei biochemischen Parametern in der Schwangerschaft. Zentralbl Gynäkol 108:1217–1221
Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, Haddow JE, Knight GJ, Palomaki GE, Canick JA (1988) Maternal serum screening for Down's syndrome in early pregnancy. Br Med J 297:883–887
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bartels, I., Bockel, B., Caesar, J. et al. Risk of fetal Down's syndrome based on maternal age and varying combinations of maternal serum markers. Arch Gynecol Obstet 255, 57–64 (1994). https://doi.org/10.1007/BF02391798
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02391798